GlassScriptPhysician profile
Kathryn M Syed
NPI 1700173440
$13,028.78
in general payments reported to CMS, 2019-2025
29 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $791 · 2021: $1,897 · 2022: $2,072 · 2023: $2,763 · 2024: $2,407 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,147.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,918.77 | 2020-2025 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $1,858.17 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,579.28 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,515.39 | 2019-2025 | Ingrezza |
| Abbvie INC. | $1,459.12 | 2019-2025 | Vraylar, Ubrelvy, Mavyret |
| Otsuka America Pharmaceutical, INC. | $1,092.89 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $698.05 | 2019-2025 | Perseris, Sublocade |
| Gilead Sciences, INC. | $653.62 | 2021-2024 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $501.50 | 2020-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $478.45 | 2023-2025 | Breztri, Andexxa, Airsupra |
| Sunovion Pharmaceuticals INC. | $295.40 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $266.02 | 2019-2024 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $216.23 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $72.56 | 2023-2024 | Secuado, Xelstrym |
| Lundbeck LLC | $68.93 | 2024-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $66.40 | 2025 | Brixadi |
| Luye Pharma (USA) LTD. | $45.12 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $39.50 | 2019-2021 | |
| Medtronic, INC. | $33.34 | 2023 | Intellis Adaptivestim |
| Allergan, INC. | $22.00 | 2019 | |
| Pfizer INC. | $20.68 | 2024 | |
| Bioxcel Therapeutics, INC. | $20.63 | 2023 | Igalmi |
| Madrigal Pharmaceuticals | $17.78 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $15.72 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $15.32 | 2025 | Auvelity |
| Lilly USA, LLC | $15.08 | 2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $15.02 | 2022 | |
| Livanova USA, INC. | $14.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.78 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.